{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:01:40Z","timestamp":1791223300090,"version":"4.1.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.clim.2007.01.006","type":"journal-article","created":{"date-parts":[[2007,2,22]],"date-time":"2007-02-22T14:42:01Z","timestamp":1172155321000},"page":"129-138","source":"Crossref","is-referenced-by-count":37,"title":["Immunobiologics in the treatment of psoriasis"],"prefix":"10.1016","volume":"123","author":[{"given":"Benjamin F.","family":"Chong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2007.01.006_bib1","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJM199912093412407","article-title":"Inflammatory skin diseases, T cells, and immune surveillance","volume":"341","author":"Robert","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2007.01.006_bib2","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/S0190-9622(03)01134-4","article-title":"The immunology of psoriasis and biologic immunotherapy","volume":"49","author":"Mehlis","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib3","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra032906","article-title":"New drugs for rheumatoid arthritis","volume":"350","author":"Olsen","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2007.01.006_bib4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00128071-200203030-00003","article-title":"Novel therapies for psoriasis","volume":"3","author":"Cather","year":"2002","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib5","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1001\/jama.256.22.3110","article-title":"Cyclosporine improves psoriasis in a double-blind study","volume":"256","author":"Ellis","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.clim.2007.01.006_bib6","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1172\/JCI118989","article-title":"Dermal injection of immunocytes induces psoriasis","volume":"98","author":"Wrone-Smith","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2007.01.006_bib7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1084\/jem.20031482","article-title":"Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha","volume":"199","author":"Boyman","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2007.01.006_bib8","doi-asserted-by":"crossref","first-page":"32633","DOI":"10.1074\/jbc.M400642200","article-title":"Effects of tumor necrosis factor-\u03b1 in epidermal keratinocytes revealed using global transcriptional profiling","volume":"279","author":"Banno","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2007.01.006_bib9","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1056\/NEJM199704103361506","article-title":"Nuclear factor-\u03baB\u2014a pivotal transcription factor in chronic inflammatory diseases","volume":"336","author":"Barnes","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2007.01.006_bib10","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/PL00000209","article-title":"Comparative quantification of IL-1\u03b2, IL-10, IL-10r, TNF-\u03b1, and IL-7 mRNA levels in UV-irradiated human skin in vivo","volume":"49","author":"Brink","year":"2000","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.clim.2007.01.006_bib11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nri1689","article-title":"Getting under the skin: the immunogenetics of psoriasis","volume":"5","author":"Bowcock","year":"2005","journal-title":"Nat. Rev., Immunol."},{"key":"10.1016\/j.clim.2007.01.006_bib12","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1172\/JCI200422147","article-title":"Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities","volume":"113","author":"Nickoloff","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2007.01.006_bib13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.clim.2007.01.006_bib14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev.immunol.14.1.233","article-title":"CD28\/B7 system of T cell costimulation","volume":"14","author":"Lenschow","year":"1996","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.clim.2007.01.006_bib15","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0952-7915(99)80046-6","article-title":"T cell co-stimulatory molecules other than CD28","volume":"11","author":"Watts","year":"1999","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.clim.2007.01.006_bib16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0196-9781(03)00083-4","article-title":"Targeting ICAM-1\/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors","volume":"24","author":"Anderson","year":"2003","journal-title":"Peptides"},{"key":"10.1016\/j.clim.2007.01.006_bib17","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.clim.2007.01.006_bib18","first-page":"1053","article-title":"A unique phenotype of skin-associated lymphocytes in humans: preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites","volume":"141","author":"Picker","year":"1992","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.clim.2007.01.006_bib19","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/383787a0","article-title":"Functional diversity of helper T lymphocytes","volume":"383","author":"Abbas","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.clim.2007.01.006_bib20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.iy.07.040189.001045","article-title":"TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties","volume":"7","author":"Mosmann","year":"1989","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.clim.2007.01.006_bib21","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1046\/j.1523-1747.1999.00749.x","volume":"113","author":"Austin","year":"1999","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib22","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.4049\/jimmunol.153.8.3639","article-title":"IL-12 regulated T helper type 1 cytokine responses in human infectious disease","volume":"153","author":"Sieling","year":"1994","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2007.01.006_bib23","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2007.01.006_bib24","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1074-7613(02)00324-2","article-title":"IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of na\u00efve CD4+ T cells","volume":"16","author":"Pflanz","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2007.01.006_bib25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.180.1.211","article-title":"Interleukin 12 synergizes with B7\/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells","volume":"180","author":"Kubin","year":"1994","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2007.01.006_bib26","first-page":"392","article-title":"Immunobiology: the immune system in health and disease","author":"Janeway","year":"2001"},{"key":"10.1016\/j.clim.2007.01.006_bib27","first-page":"107","article-title":"The potential of interleukin 12 inhibition in the treatment of psoriasis","volume":"141","author":"Rosmarin","year":"2005","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clinbiochem.2005.11.008","article-title":"The role of interleukin-12 in the pathogenesis of psoriasis","volume":"39","author":"Shaker","year":"2006","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.clim.2007.01.006_bib29","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1046\/j.1523-1747.1998.00446.x","article-title":"Expression of interleukin-12 is increased in psoriatic skin","volume":"111","author":"Yawalkar","year":"1998","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib30","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000018222","article-title":"Effects of cyclosporine A on immune activation markers in patients with active psoriasis","volume":"199","author":"Economidou","year":"1999","journal-title":"Dermatology"},{"key":"10.1016\/j.clim.2007.01.006_bib31","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1084\/jem.181.2.747","article-title":"Bacterial superantigens induce T cell expression of the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen, via stimulation of interleukin-12 production","volume":"181","author":"Leung","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2007.01.006_bib32","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.4049\/jimmunol.176.3.1908","article-title":"In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin","volume":"176","author":"Piskin","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2007.01.006_bib33","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1046\/j.1523-1747.1998.00347.x","article-title":"Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes","volume":"111","author":"Teunissen","year":"1998","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib34","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.immuni.2006.06.002","article-title":"Th17: an effector CD4 T cell lineage with regulatory T cell ties","volume":"24","author":"Weaver","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2007.01.006_bib35","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/art.21491","article-title":"The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study","volume":"54","author":"Finckh","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.01.006_bib36","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nbt0698-535","article-title":"Human antibodies by design","volume":"16","author":"Vaughan","year":"1998","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.clim.2007.01.006_bib37","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.4049\/jimmunol.140.5.1401","article-title":"Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-gamma production","volume":"140","author":"Sanders","year":"1988","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2007.01.006_bib38","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.4049\/jimmunol.168.9.4462","article-title":"Alefacept, an immunomodulatory recombinant LFA-3\/IgG1 fusion protein, induces CD16 signaling and CD2\/CD16-dependent apoptosis of CD2+ cells","volume":"168","author":"da Silva","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2007.01.006_bib39","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/eji.200323586","article-title":"Alefacept selectively promotes NK cell-mediated deletion of CD45RO+ human T cells","volume":"33","author":"Cooper","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2007.01.006_bib40","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/archderm.139.12.1563","article-title":"Alefacept Clinical Study Group, treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts","volume":"139","author":"Gordon","year":"2003","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib41","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis\u2014oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"issue":"Suppl. 2","key":"10.1016\/j.clim.2007.01.006_bib42","doi-asserted-by":"crossref","first-page":"ii65","DOI":"10.1136\/ard.2004.031237","article-title":"Psoriasis assessment tools in clinical trials","volume":"64","author":"Feldman","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2007.01.006_bib43","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00403-004-0450-y","article-title":"Alefacept therapy reduces the effector T cell population in lesional psoriatic epidermis","volume":"473","author":"Goedkoop","year":"2004","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.clim.2007.01.006_bib44","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1073\/pnas.0409569102","article-title":"Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris","volume":"102","author":"Chamian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2007.01.006_bib45","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0190-9622(03)01836-X","article-title":"CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study","volume":"49","author":"Gottlieb","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib46","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jaad.2003.09.014","article-title":"A 50% reduction in the psoriasis area and severity index is a clinically significant endpoint in the assessment of psoriasis","volume":"50","author":"Carlin","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib47","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.139.6.719","article-title":"Alefacept Study Group, an international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis","volume":"139","author":"Lebwohl","year":"2003","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib48","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.sder.2005.01.001","article-title":"Alefacept for the treatment of psoriasis: a review of the current literature and practical suggestions for everyday clinical use","volume":"24","author":"Korman","year":"2005","journal-title":"Semin. Cutan. Med. Surg."},{"issue":"Suppl. 2","key":"10.1016\/j.clim.2007.01.006_bib49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1468-3083.17.s2.4.x","article-title":"Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis","volume":"17","author":"Krueger","year":"2003","journal-title":"J. Eur. Acad. Dermatol. Venerol."},{"key":"10.1016\/j.clim.2007.01.006_bib50","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.clinthera.2005.12.007","article-title":"An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy","volume":"27","author":"Goffe","year":"2005","journal-title":"Clin. Ther."},{"key":"10.1016\/j.clim.2007.01.006_bib51","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.det.2004.03.014","article-title":"Current concepts and review of alefacept in the treatment of psoriasis","volume":"22","author":"Krueger","year":"2004","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.clim.2007.01.006_bib52","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000077660","article-title":"T-cell modulation for the treatment of chronic plaque psoriasis with Efalizumab (Raptiva): mechanisms of action","volume":"208","author":"Jullien","year":"2004","journal-title":"Dermatology"},{"key":"10.1016\/j.clim.2007.01.006_bib53","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clim.2004.06.001","article-title":"Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin","volume":"113","author":"Vugmeyster","year":"2004","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2007.01.006_bib54","doi-asserted-by":"crossref","first-page":"19057","DOI":"10.1073\/pnas.0509736102","article-title":"Increase in TNF-\u03b1 and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)","volume":"102","author":"Lowes","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2007.01.006_bib55","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1001\/jama.290.23.3073","article-title":"Efalizumab Study Group, Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial","volume":"290","author":"Gordon","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.clim.2007.01.006_bib56","first-page":"614","article-title":"Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis","volume":"3","author":"Gottlieb","year":"2004","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib57","first-page":"77","article-title":"Generalized pustular psoriasis following withdrawal of efalizumab","volume":"3","author":"Gaylor","year":"2004","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib58","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1365-2133.2005.06818.x","article-title":"Ingestion of topical steroid triggering pustular psoriasis?","volume":"153","author":"Orpin","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib59","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-5945-5-9","article-title":"Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series","volume":"5","author":"Lowes","year":"2005","journal-title":"BMC Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib60","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1084\/jem.174.6.1483","article-title":"A tumor necrosis factor (TNF) receptor\u2013IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity","volume":"174","author":"Peppel","year":"1991","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2007.01.006_bib61","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.0022-202X.2005.23735.x","article-title":"Differential expression of phosphorylated NF-kappaB\/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept","volume":"124","author":"Lizzul","year":"2005","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib62","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.4049\/jimmunol.175.4.2721","article-title":"TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques","volume":"175","author":"Gottlieb","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2007.01.006_bib63","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/archderm.139.12.1627","article-title":"A randomized trial of etanercept as monotherapy for psoriasis","volume":"139","author":"Gottlieb","year":"2003","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib64","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/mjd.2003.554","article-title":"Etanercept: an overview","volume":"49","author":"Goffe","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib65","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/art.11033","article-title":"Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis","volume":"48","author":"Carlson","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.01.006_bib66","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jaad.2005.04.011","article-title":"Biologics in psoriasis: a quick reference guide","volume":"53","author":"Thomas","year":"2005","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib67","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/gut.50.2.206","article-title":"Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease","volume":"50","author":"ten Hove","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.clim.2007.01.006_bib68","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1067\/mjd.2003.10","article-title":"Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-\u03b1 monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris","volume":"48","author":"Gottlieb","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib69","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.clim.2007.01.006_bib70","doi-asserted-by":"crossref","first-page":"R326","DOI":"10.1186\/ar1182","article-title":"Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study","volume":"6","author":"Goedkoop","year":"2004","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.clim.2007.01.006_bib71","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2133.2005.07078.x","article-title":"Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis","volume":"154","author":"Kr\u00fcger-Krasagakis","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib72","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"EXPRESS study investigators, Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2007.01.006_bib73","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"issue":"Suppl. 3","key":"10.1016\/j.clim.2007.01.006_bib74","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1086\/429996","article-title":"Reactivation of latent granulomatous infections by infliximab","volume":"41","author":"Wallis","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.clim.2007.01.006_bib75","first-page":"546","article-title":"Life-threatening pustular and erythrodermic psoriasis responding to infliximab","volume":"5","author":"Lewis","year":"2006","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib76","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.sder.2005.01.005","article-title":"Potential future therapies for psoriasis","volume":"24","author":"Papp","year":"2005","journal-title":"Semin. Cutan. Med. Surg."},{"key":"10.1016\/j.clim.2007.01.006_bib77","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1365-2133.2005.06816.x","article-title":"The tumor necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques","volume":"153","author":"Gordon","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib78","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study","volume":"55","author":"Gordon","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib79","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1016\/j.jaad.2005.03.062","article-title":"Distal lower extremity paresthesia and foot drop developing during adalimumab therapy","volume":"53","author":"Berthelot","year":"2005","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clim.2007.01.006_bib80","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2007.01.006_bib81","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1396-0296.2004.04045.x","article-title":"Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis","volume":"17","author":"Patel","year":"2004","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.clim.2007.01.006_bib82","doi-asserted-by":"crossref","first-page":"7480","DOI":"10.4049\/jimmunol.162.12.7480","article-title":"IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder","volume":"15","author":"Hong","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2007.01.006_bib83","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/j.0022-202X.2004.23448.x","article-title":"A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis","volume":"123","author":"Kauffman","year":"2004","journal-title":"J. Invest. Dermatol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661607000022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661607000022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T04:44:01Z","timestamp":1707626641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661607000022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":83,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S1521661607000022"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2007.01.006","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}